The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies
Open accessAbstract
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B‐cell‐mediated lymphoproliferative disorders. Ibrutinib, however, carries an increased bleeding risk compared with standard chemotherapy. Bleeding events range from minor mucocutaneous bleeding to life‐threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways. There is currently a minimal amount of data to guide clinicians regarding the use of ibrutinib in patients at high risk of bleeding or on anticoagulant or antiplatelet therapy. In addition, the potential cardiovascular protective effects of ibrutinib monotherapy in patients at risk of vascular disease are unknown. Patients should be cautioned against using non‐steroidal anti‐inflammatory drugs, fish oils, vitamin E and aspirin‐containing products, and consider replacing ibrutinib with a different agent if dual antiplatelet therapy is indicated. Patients should not take vitamin K antagonists concurrently with ibrutinib; direct oral anticoagulants should be used if extended anticoagulation is strongly indicated. In this review, we describe the pathophysiology of ibrutinib‐mediated bleeding and suggest risk reduction strategies for common clinical scenarios associated with ibrutinib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Dewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Aspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 942
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Baharoglu, M. I., Cordonnier, C., Salman, R. A.-S., de Gans, K., Koopman, M. M., Brand, A., Majoie, C. B., Beenen, L. F., Marquering, H. A., Vermeulen, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30392-0 · Cited by 766
Peters, R. J. G., Mehta, S. R., Fox, K. A. A., Zhao, F., Lewis, B. S., Kopecky, S. L., Diaz, R., Commerford, P. J., Valentin, V., & Yusuf, S. (2003) · Circulation · doi:10.1161/01.cir.0000091201.39590.cb · Cited by 706
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Kremer Hovinga, J. A., Cataland, S., Knöbl, P., Wu, H., Artoni, A., Westwood, J.-P., Mansouri Taleghani, M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 666
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.021 · Cited by 576
A Crucial Role of Glycoprotein VI for Platelet Recruitment to the Injured Arterial Wall In Vivo
Massberg, S., Gawaz, M., Grüner, S., Schulte, V., Konrad, I., Zohlnhöfer, D., Heinzmann, U., & Nieswandt, B. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20020945 · Cited by 516
Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00667-4 · Cited by 463
Primary B Cell Immunodeficiencies: Comparisons and Contrasts
Conley, M. E., Dobbs, A. K., Farmer, D. M., Kilic, S., Paris, K., Grigoriadou, S., Coustan-Smith, E., Howard, V., & Campana, D. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132649 · Cited by 426
Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R. S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00465-9 · Cited by 415
Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
McMullen, J. R., Boey, E. J. H., Ooi, J. Y. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. (2014) · Blood · doi:10.1182/blood-2014-10-604272 · Cited by 403
Leese, P. T., Hubbard, R. C., Karim, A., Isakson, P. C., Yu, S. S., & Geis, G. S. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008766 · Cited by 371
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Chai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Levade, M., David, E., Garcia, C., Laurent, P.-A., Cadot, S., Michallet, A.-S., Bordet, J.-C., Tam, C., Sié, P., Ysebaert, L., et al. (2014) · Blood · doi:10.1182/blood-2014-06-583294 · Cited by 321
Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2
Herzog, B. H., Fu, J., Wilson, S. J., Hess, P. R., Sen, A., McDaniel, J. M., Pan, Y., Sheng, M., Yago, T., Silasi-Mansat, R., et al. (2013) · Nature · doi:10.1038/nature12501 · Cited by 317
Walter, H. S., Rule, S. A., Dyer, M. J. S., Karlin, L., Jones, C., Cazin, B., Quittet, P., Shah, N., Hutchinson, C. V., Honda, H., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664086 · Cited by 268
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Wu, J., Zhang, M., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0250-9 · Cited by 254
A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen
Quek, L. S., Bolen, J., & Watson, S. P. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70471-3 · Cited by 253
Primary Immunodeficiency Diseases Due to Defects in Lymphocytes
Buckley, R. H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431806 · Cited by 244
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Leong, D. P., Caron, F., Hillis, C., Duan, A., Healey, J. S., Fraser, G., & Siegal, D. (2016) · Blood · doi:10.1182/blood-2016-05-712828 · Cited by 233
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
Kamel, S., Horton, L., Ysebaert, L., Levade, M., Burbury, K., Tan, S., Cole-Sinclair, M., Reynolds, J., Filshie, R., Schischka, S., et al. (2015) · Leukemia · doi:10.1038/leu.2014.247 · Cited by 231
GPVI and CLEC‐2 in hemostasis and vascular integrity
WATSON, S. P., HERBERT, J. M. J., & POLLITT, A. Y. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03875.x · Cited by 210
de Abajo, F. J. (2011) · Drugs & Aging · doi:10.2165/11589340-000000000-00000 · Cited by 206
A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic Plaques
Reininger, A. J., Bernlochner, I., Penz, S. M., Ravanat, C., Smethurst, P., Farndale, R. W., Gachet, C., Brandl, R., & Siess, W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.051 · Cited by 186
Lipsky, A. H., Farooqui, M. Z. H., Tian, X., Martyr, S., Cullinane, A. M., Nghiem, K., Sun, C., Valdez, J., Niemann, C. U., Herman, S. E. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.126672 · Cited by 172
Liu, J., Fitzgerald, M. E. C., Berndt, M. C., Jackson, C. W., & Gartner, T. K. (2006) · Blood · doi:10.1182/blood-2006-01-011817 · Cited by 138
Impact of glycoprotein VI and platelet adhesion on atherosclerosis—A possible role of fibronectin
Bültmann, A., Li, Z., Wagner, S., Peluso, M. V., Schönberger, T., Weis, C., Konrad, I., Stellos, K., Maßberg, S., Nieswandt, B., et al. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.04.009 · Cited by 135
Ponader, S., & Burger, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1046 · Cited by 132
Yuan, Y., Kulkarni, S., Ulsemer, P., Cranmer, S. L., Yap, C. L., Nesbitt, W. S., Harper, I. S., Mistry, N., Dopheide, S. M., Hughan, S. C., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36241 · Cited by 115
Kuijpers, M. J. E., Gilio, K., Reitsma, S., Nergiz‐Unal, R., Prinzen, L., Heeneman, S., Lutgens, E., van Zandvoort, M. A. M. J., Nieswandt, B., Egbrink, M. G. A. O., et al. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03186.x · Cited by 113
Bye, A. P., Unsworth, A. J., Vaiyapuri, S., Stainer, A. R., Fry, M., & Gibbins, J. M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306130 · Cited by 113
Bender, M., Hagedorn, I., & Nieswandt, B. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04328.x · Cited by 109
The evolution of antiplatelet therapy in cardiovascular disease
Yousuf, O. K., & Bhatt, D. L. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.96 · Cited by 105
The physiological and pathophysiological roles of platelet CLEC-2
Langan, S. A., Nash, G. B., Watson, S. P., & Navarro‐Núñez, L. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-01-0060 · Cited by 105
de Zwart, L., Snoeys, J., de Jong, J. D., Sukbuntherng, J., Mannaert, E., & Monshouwer, M. (2016) · Clinical pharmacology and therapy · doi:10.1002/cpt.419 · Cited by 103
Manne, B. K., Badolia, R., Dangelmaier, C., Eble, J. A., Ellmeier, W., Kahn, M. L., & Kunapuli, S. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629527 · Cited by 90
Cosemans, J. M. E. M., Kuijpers, M. J. E., Lecut, C., Loubele, S. T. B. G., Heeneman, S., Jandrot‐Perrus, M., & Heemskerk, J. W. M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.037 · Cited by 89
Futatani, T., Watanabe, C., Baba, Y., Tsukada, S., & Ochs, H. D. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02905.x · Cited by 86
Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function
Rigg, R. A., Aslan, J. E., Healy, L. D., Wallisch, M., Thierheimer, M. L. D., Loren, C. P., Pang, J., Hinds, M. T., Gruber, A., & McCarty, O. J. T. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00325.2015 · Cited by 84
Self-citationComparison of two murine models of thrombosis induced by atherosclerotic plaque injury
Hechler, B., & Gachet, C. (2011) · Thrombosis and Haemostasis · doi:10.1160/ths10-11-0730 · Cited by 63
The VWF-GPIb axis in ischaemic stroke: lessons from animal models
Denorme, F., & Meyer, S. F. D. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0036 · Cited by 48
Kazianka, L., Drucker, C., Skrabs, C., Thomas, W., Melchardt, T., Struve, S., Bergmann, M. M., Staber, P. B., Porpaczy, E. A., Einberger, C., et al. (2016) · Leukemia · doi:10.1038/leu.2016.316 · Cited by 43
Finnes, H. D., Rabe, K. G., Call, T. G., Ding, W., Kenderian, S. S., Bowen, D. A., Conte, M. J., McCullough, K. B., Merten, J. A., Bartoo, G. T., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1251592 · Cited by 41
AHL, J. S. B., Perahia, Bangs, M. E., Zhang, Cheng, Y., Frakes, E. P., Adams, M. L., & Martinez, J. M. (2013) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s45445 · Cited by 26
Seiter, K. P., Stiefel, M., Barrientos, J. C., Shaikh, A. U., Ahmed, N. U., Baskind, P., & Liu, D. (2016) · Stem Cell Investigation · doi:10.21037/sci.2016.06.08 · Cited by 22
Cited by
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Tam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Sanz, R. G., et al. (2020) · Blood · doi:10.1182/blood.2020006844 · Cited by 466
Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 380
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
Estupiñán, H. Y., Berglöf, A., Zain, R., & Smith, C. I. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630942 · Cited by 267
Metadata
- Authors
- Shatzel, J. J., Olson, S. R., Tao, D. L., McCarty, O. J. T., Danilov, A. V., & DeLoughery, T. G.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 15
- Issue
- 5
- Pages
- 835-847
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2587387808
- Cited by
- 279
- References
- 60
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.